Earnings summaries and quarterly performance for Verrica Pharmaceuticals.
Executive leadership at Verrica Pharmaceuticals.
Board of directors at Verrica Pharmaceuticals.
Research analysts who have asked questions during Verrica Pharmaceuticals earnings calls.
Kemp Dolliver
Brookline Capital Markets
4 questions for VRCA
Also covers: BIOX, EYEN, ICCM +4 more
SK
Stacy Ku
TD Cowen
4 questions for VRCA
Also covers: AUPH, BCRX, KALV +3 more
SB
Serge Belanger
Needham & Company
3 questions for VRCA
Also covers: AMPH, ARQT, BCRX +12 more
DD
Dennis Ding
Jefferies Financial Group Inc.
2 questions for VRCA
Also covers: ARDX, CARA, FOLD +6 more
AN
Anish Nikhanj
RBC Capital Markets
1 question for VRCA
Also covers: APTO, CRMD, EXEL +6 more
GS
Glen Santangelo
Jefferies
1 question for VRCA
Also covers: ALGN, ANIP, BHC +12 more
Gregory Renza
RBC Capital Markets
1 question for VRCA
Also covers: ACAD, ADCT, AGIO +12 more
JT
John Todaro
Needham & Company
1 question for VRCA
Also covers: APLD, BTDR, CAN +12 more
OL
Oren Livnat
H.C. Wainwright
1 question for VRCA
Also covers: ANIP, AVDL, CARA +7 more
Recent press releases and 8-K filings for VRCA.
Veradermics Completes Enrollment in Phase 2/3 Clinical Trial for Male Pattern Hair Loss Treatment
VRCA
New Projects/Investments
Product Launch
- Veradermics has completed enrollment in its Phase 2/3 clinical trial for VDPHL01, an extended-release oral minoxidil for male pattern hair loss.
- VDPHL01 is positioned as the potential first-ever extended-release oral minoxidil and, if approved, would be the first and only non-hormonal oral treatment for male pattern hair loss.
- The company is also actively enrolling participants for a second Phase 3 male trial and a Phase 2/3 trial in females, with full Phase 2 data expected in 2026.
Dec 11, 2025, 12:00 PM
Verrica Pharmaceuticals Reports Q3 2025 Financial Results and Pipeline Advancements
VRCA
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Verrica Pharmaceuticals reported total revenue of $14.3 million for Q3 2025, a significant increase from negative $1.8 million in Q3 2024, and achieved a non-GAAP net income of $1.2 million, or $0.13 per share.
- YCANTH dispensed applicator units grew approximately 5% sequentially to 14,093 in Q3 2025, and 120% year-over-year for the nine months ended September 30, 2025, reaching 37,642 units. The company plans to launch YCANTH Rx, a new non-dispensing pharmacy, in Q4 2025.
- The company is advancing its pipeline, with the global Phase III clinical program for YCANTH in common warts expected to begin in December 2025, and FDA alignment on the Phase III study design for VP-315 for basal cell carcinoma.
- Verrica received $10 million in cash milestone payments from Torii in Q3 2025, contributing to $18 million received year-to-date, with cash and cash equivalents totaling $21.1 million as of September 30, 2025.
Nov 17, 2025, 1:30 PM
Verrica Pharmaceuticals Reports Q3 2025 Financial Results and Pipeline Progress
VRCA
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Verrica Pharmaceuticals reported total revenue of $14.3 million for Q3 2025, a significant increase from a negative $1.8 million in Q3 2024, primarily driven by $10.7 million in Torii milestone and collaboration revenue and $3.6 million in net YCANTH revenue.
- The company achieved a non-GAAP net income of $1.2 million or $0.13 per share in Q3 2025, a substantial improvement from a net loss of $20.2 million or $4.30 per share in Q3 2024.
- YCANTH dispensed applicator units reached 14,093 in Q3 2025, representing 5% sequential growth, and increased 120% year-over-year to 37,642 units for the nine months ended September 30, 2025.
- Verrica is advancing its pipeline, with the global phase III clinical program for YCANTH in common warts expected to begin in December, and has reached alignment with the FDA on the phase III study design for VP-315 for basal cell carcinoma.
- Cash and cash equivalents stood at $21.1 million as of September 30, 2025, bolstered by $18 million in cash milestone payments from Torii during 2025, with $10 million received in Q3.
Nov 17, 2025, 1:30 PM
Verrica Pharmaceuticals Reports Strong Q3 2025 Revenue Growth and Pipeline Advancement
VRCA
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Verrica Pharmaceuticals reported total revenue of $14.3 million for Q3 2025, a significant increase from a negative $1.8 million in Q3 2024, and achieved Non-GAAP net income of $1.2 million, or $0.13 per share.
- YCANTH dispensed applicator units grew 5% sequentially to 14,093 in Q3 2025, with year-to-date units increasing 120% over the same period in 2024 to 37,642.
- The company received $10 million in milestone payments in Q3 2025 following YCANTH's approval in Japan for molluscum, and anticipates filing for marketing authorization in the EU as early as Q4 2026.
- Verrica is advancing its pipeline, with the global Phase 3 program for YCANTH in common warts expected to begin in December 2025, and has received positive FDA feedback for the Phase 3 development of VP-315 for basal cell carcinoma.
- As of September 30, 2025, Verrica held $21.1 million in cash and cash equivalents, funding operations into late Q4 2025.
Nov 17, 2025, 1:30 PM
Verrica Pharmaceuticals Reports Q3 2025 Financial Results and Key Milestones
VRCA
Earnings
Product Launch
New Projects/Investments
- Verrica Pharmaceuticals reported $14.3 million in total revenue for the third quarter ended September 30, 2025, consisting of $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue.
- For Q3 2025, the company achieved a net loss of $0.3 million, or $0.03 per basic and diluted share, and a non-GAAP net income of $1.2 million, or $0.13 per basic and diluted share.
- Verrica received a $10 million cash milestone payment in September 2025 following the approval of YCANTH for molluscum in Japan.
- The company received positive feedback from the FDA regarding the study design for a Phase 3 program for VP-315 in basal cell carcinoma and from the European Medicines Agency supporting a Marketing Authorization Application filing for YCANTH for molluscum without the need for additional Phase 3 studies.
Nov 14, 2025, 9:25 PM
Veradermics Announces Oversubscribed $150 Million Series C Financing
VRCA
New Projects/Investments
Board Change
- Veradermics announced the completion of an oversubscribed $150 million Series C financing.
- The proceeds are intended to fund the advancement of VDPHL01, an investigational extended-release oral minoxidil, through multiple ongoing Phase 3 clinical trials and a planned New Drug Application (NDA) submission for the treatment of pattern hair loss.
- Preliminary Phase 2 data in males for VDPHL01 showed visible and measurable hair growth as early as two months, with an average increase of 37.5 hairs/cm2 from baseline at two months and 47.3 hairs/cm2 at four months.
- The financing was led by SR One, with participation from new investors including Viking Global Investors and Marshall Wace.
- Katarina Pance, Ph.D., an investor at SR One, has joined Veradermics' board of directors.
Oct 16, 2025, 11:30 AM
Verrica Pharmaceuticals outlines new strategic vision and pipeline progress
VRCA
CEO Change
CFO Change
New Projects/Investments
- Verrica Pharmaceuticals' new CEO, Jayson Rieger, and CFO, John Kirby, who started in November, implemented a strategic vision that included reducing expenses, securing the balance sheet with a $42 million funding round in November, and reworking the YCANTH launch strategy.
- The company is expanding YCANTH's market access for molluscum contagiosum by targeting pediatricians alongside dermatologists and utilizing specialty pharmacies and local pharmacies, moving away from a pure buy-and-bill model. This strategy has led to an uptick in product dispensed despite sales force resizing to 35 representatives.
- Verrica is advancing its pipeline with a global Phase 3 program for Common Warts (VP-102) in collaboration with Torii Pharmaceutical, which could expand the market by 3 to 3.5 times the molluscum market with a 20 million prevalence.
- Additionally, the company reported strong data for VP-315 for basal cell carcinoma, showing a near 50% reduction to complete histological clearance and a 97% objective response rate with no serious adverse events.
Mar 3, 2025, 7:30 PM
Verrica Pharmaceuticals Outlines New Strategic Vision and Pipeline Updates
VRCA
Management Change
New Projects/Investments
- Jayson Rieger (CEO) and John Kirby (CFO) started in November, implementing a new strategic vision that included reducing expenses and securing a $42 million funding round in November.
- The commercial strategy for YCANTH has been revamped, shifting from a buy-and-bill model to utilizing specialty and local independent pharmacies for distribution and insurance management, and expanding educational outreach to pediatricians alongside dermatologists.
- Verrica is advancing its pipeline with a global Phase III program for common warts (VP-102) in partnership with Torii Pharmaceutical, targeting a market 3 to 3.5 times larger than molluscum with 20 million prevalence, and plans a Phase III meeting for VP-315 in basal cell carcinoma following Phase II data showing near 50% complete histological clearance and a 97% objective response rate.
- YCANTH maintains strong patent exclusivity, extending from 2034 to potentially 2041.
Mar 3, 2025, 7:30 PM
Quarterly earnings call transcripts for Verrica Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more